Summary: 

        IPG1094 is a pioneering, first-in-class, blood-brain barrier (BBB)-penetrant small-molecule inhibitor of Macrophage Migration Inhibitory Factor (MIF) tautomerase activity. It is the world's first selective MIF inhibitor to advance to clinical development, positioning it as a groundbreaking therapeutic candidate with unique dual-action potential in both immuno-oncology and neurology.

        By precisely targeting the enzymatic activity of MIF, IPG1094 is designed to address two distinct areas of high unmet medical need: reversing tumor-induced immunosuppression for the treatment of brain metastases, and reducing neuroinflammation to provide a disease-modifying therapy for acute ischemic stroke. With its novel chemical structure, favorable safety profile established in the completed Phase 1 trial, and significant first-mover advantage, IPG1094 holds the potential to become a transformative therapy across multiple high-value indications.

IPG1094 in Oncology 

Mechanism of Action

￭ In the tumor microenvironment, many cancers secrete MIF via exosomes. This process drives the recruitment, expansion, and immunosuppressive function of myeloid-derived suppressor cells (MDSCs)—a dominant immunosuppressive population that abrogates the antitumor activity of CD8+ cytotoxic T cells, allowing tumors to evade immune surveillance.

￭ IPG1094 potently inhibits the MIF tautomerase activity essential for this cascade, thereby reducing MDSC generation and function, restoring CD8+ T cell-mediated antitumor immunity, and directly suppressing tumor growth and metastasis.

Key Differentiation

￭Exceptional Brain Penetration: Its unique ability to cross the blood-brain barrier (BBB) addresses a major unmet medical need where most systemic therapies fail to achieve therapeutic concentrations in brain metastases.

￭ Precision Immuno-Oncology: By selectively targeting the MIF signaling axis on myeloid cells, IPG1094 reprograms the tumor microenvironment without the risks of broad systemic immune suppression.

￭ Synergistic Combination Potential: Its distinct mechanism of action supports synergistic use with standard-of-care therapies, including radiotherapy and immune checkpoint inhibitors, to improve patient outcomes.

Current Development & Status

￭ Phase 1/2a (Ongoing): A multi-center, open-label clinical trial in patients with advanced primary or metastatic malignant brain tumors is actively progressing in China.

￭ Upcoming Milestones: Following completion of the current trial, a pivotal Phase 2 study is planned to evaluate IPG1094 in combination with whole-brain radiotherapy (WBRT) for non-small cell lung cancer (NSCLC) patients with brain metastases.

Clinical Studies

￭ Pilot clinical studies in glioblastoma and lung cancer brain metastases demonstrate that IPG1094 treatment resulted in significant tumor shrinkage, marked resolution of cerebral edema, and substantial improvement in brain tumor-associated symptoms including fatigue, nausea, and headache. These benefits were associated with markedly prolonged progression-free survival (PFS). 

￭ Phase 2 trials in lung cancer brain metastases (the lead indication) are currently underway.

In vitro properties 

￭ Reverses Tumor-Induced Immune Suppression: In vitro studies confirm that IPG1094 completely abrogates the generation of immunosuppressive MDSCs induced by pancreatic cancer-derived exosomes and fully restores the proliferative capacity of tumor-killing CD8+ cytotoxic T cells.

In vivo Properties

￭Dose-Dependent Tumor Growth Inhibition: In a subcutaneous pancreatic cancer mouse model, IPG1094 treatment demonstrated significant, dose-dependent inhibition of tumor growth compared to vehicle control.

IPG1094 in ischemic stroke

Mechanism of Action

￭ During acute ischemic stroke, MIF acts as a key upstream pro-inflammatory cytokine that is rapidly and markedly upregulated. It initiates and amplifies the pathological cascade by promoting blood-brain barrier (BBB) disruption, cerebral edema, glial cell activation, and neuronal cell death—processes that cause permanent neurological disability.

￭ By inhibiting MIF tautomerase activity at the apex of this inflammatory hierarchy, IPG1094 interrupts these damaging pathways, thereby preserving BBB integrity, reducing neuronal apoptosis, limiting infarct volume, and mitigating long-term neurological deficits.

Key Differentiation

■ Disease-Modifying Neuroprotection: Unlike standard-of-care therapies (thrombolysis and mechanical thrombectomy) that only restore blood flow, IPG1094 directly targets the secondary neuroinflammatory cascade responsible for most long-term disability.

■ Extended Therapeutic Window: Its unique mechanism positions it as a potential therapy capable of providing neuroprotection beyond the narrow acute reperfusion window, potentially benefiting a much larger patient population.

■ Direct CNS Activity: IPG1094's robust BBB penetration allows it to act directly within the central nervous system, where ischemic damage occurs.

Current Development & Status

￭ Phase 1 (Completed): The completed Phase 1 trial in healthy subjects provides a strong safety and tolerability foundation for its development in the acute stroke patient population.

￭ Phase 2 Initiation: IND applications for ischemic stroke have been approved by the FDA. A Phase 2 clinical trial is anticipated to commence to evaluate its efficacy and safety in acute ischemic stroke patients.

Clinical Studies

￭ Phase I clinical trial indicated no severe (> grade 2) AE during dose escalation from 100 mg to 1200 mg, with linear dose-exposure relationship.

In vivo Properties

￭ In a highly translatable stroke model using spontaneously hypertensive rats (SHRs), IPG1094 treatment significantly reduced the area of cerebral infarction.

.

￭ This neuroprotective effect was accompanied by a robust and dose-dependent improvement in neurological and sensorimotor functions, including motor coordination, muscle strength, and endurance.

Publication

•Jia X, Xi J, Tian B, Zhang Y, Wang Z, Wang F, Li Z, Long J, Wang J, Fan GH, Li Q. The Tautomerase Activity of Tumor Exosomal MIF Promotes Pancreatic Cancer Progression by Modulating MDSC Differentiation. Cancer Immunol Res. 2024 Jan 3;12(1):72-90. doi: 10.1158/2326-6066.CIR-23-0205. PMID: 37956411.